Business / Finance

RSS

TSX approves Aeterna Zentaris' Series B Warrant amendment

Aeterna Zentaris Inc. announced today that The Toronto Stock Exchange has approved its previously announced amendment to its outstanding Series B Common Share Purchase Warrants agreed to with the holders of approximately 90% of the holders of the Series B Warrants intended to reduce the dilutive effect of the exercise of the Series B Warrants by establishing a cap on the number of shares issuable upon alternate net cashless exercise of the Series B Warrants until the close of business on November 17, 2015 and by limiting the number of shares that the Consenting Holders may sell until the close of business on October 9, 2015.

26 Sep 2015

Genovate begins construction of Insulin Ecological Industrial Park in Changzhou National Hi-tech District

On September 22, construction of phase I of Genovate Biotechnology's Insulin Ecological Industrial Park began in Changzhou National Hi-tech District. Changzhou mayor Fei Gaoyun said the city and district governments and the relevant oversight authorities will do their best to provide support services, with the aim of doing what is needed to see construction completed and the facility put into production as early as possible.

26 Sep 2015

Apax-advised funds sign definitive agreement to acquire interest in Ideal Protein

Funds advised by Apax Partners LLP, a global private equity firm, today announced that they have entered into a definitive agreement to acquire an interest in Ideal Protein, a proprietary weight loss and wellness solutions company. Terms of the transaction were not disclosed.

26 Sep 2015

Cryoport purchases IP rights to Cryoportal operating platform from Klatu

Cryoport, Inc. today announced the purchase of certain intellectual property and intellectual property rights to the Cryoportal operating platform from KLATU Networks, LLC.

24 Sep 2015

Florida Institute finalizes funding agreement with Aviana

The Florida Institute for the Commercialization of Public Research announced today that it has finalized a funding agreement with Aviana Molecular Technologies, an Orlando-based company with technology developed at the University of Central Florida.

24 Sep 2015

ElastiMed raises $1 million investment

ElastiMed, a portfolio company of Trendlines Medical, announced this week that it raised $1 million, which includes an investment from Pix Vine Capital, a Singapore-based investment house.

24 Sep 2015

Johns Hopkins trained physicians create start-up to produce cheap generic drugs

A group of Johns Hopkins trained physicians has started a crowdfunding campaign to create a start-up which produces cheap generic drugs.

23 Sep 2015

Medgen completes acquisition of Alternaturals

Medgen, Inc. today announced that it has completed the acquisition of Alternaturals, the operating subsidiary of Alternaturals, Inc., and a popular alternative healthcare and natural remedies company. The acquisition was made in an effort to increase the company's consumer reach and revenue base, and could be the most exciting event in several years, positioning the company to take some major steps forward.

22 Sep 2015

PDL BioPharma purchases portion of royalties on expected sales of AcelRx's Zalviso

PDL BioPharma, Inc. announced today that it has acquired a portion of the royalties on expected sales of AcelRx Pharmaceuticals Inc.'s Zalviso (sufentanil sublingual tablet system) in the European Union, Switzerland and Australia by its commercial partner, Grunenthal.

21 Sep 2015

Palatin Technologies reports net loss of $12.1 million for fourth quarter 2015

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2015.

21 Sep 2015

Mölnlycke Health Care selects Mindtree to improve SAP application management

Mindtree, a leading digital transformation and technology services company, today announced that it has been selected by Mölnlycke Health Care, a world-leading provider of single-use surgical and wound care solutions, to enhance business efficiency using the SAP application suite. This will help Mölnlycke Health Care optimize the time to market of its products.

21 Sep 2015

Takeda Pharmaceutical's $2.37 billion settlement over Actos drug moves forward

MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that Takeda Pharmaceutical Co.'s $2.37 billion settlement over their diabetes drug Actos is going through and moving forward. Actos drug maker, Takeda, agreed to toss in another $100 million if enough claimants signed up with matching settlement criteria – 97% of the claims to be exact.

21 Sep 2015

Glide Technologies, Cilian collaborate to develop solid dose formulation of recombinant influenza vaccine

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines, today announced that it has entered a collaboration with German biotechnology company Cilian AG to develop a solid dose formulation of Cilian's experimental recombinant influenza vaccine, CiFlu, for delivery using Glide's patient-friendly SDI delivery device.

21 Sep 2015

Quethera receives seed investment funding to develop gene therapy for glaucoma

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven’s Rainbow Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

18 Sep 2015

CardioDx announces national agreement with Quest Diagnostics to expand access to Corus CAD blood test

CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced a national specimen-draw agreement with Quest Diagnostics DGX, +1.23% the world's leading provider of diagnostic information services, that will expand patient and clinician access to the Corus CAD lab-developed blood test for aiding the assessment of obstructive coronary artery disease (CAD).

From Quest Diagnostics 18 Sep 2015

Immune Pharmaceuticals’ CEO establishes stock trading plan

Immune Pharmaceuticals, Inc. announced today that its Chief Executive Officer, Dr. Daniel Teper, has established a stock trading plan with respect to the purchases of up to an aggregate of $250,000 of shares of Immune common stock in accordance with Rule 10b5-1 under the Exchange Act and other applicable federal securities laws and regulations adopted by the Securities and Exchange Commission.

16 Sep 2015

Vomaris signs exclusive global commercial partnership with Metrex for Procellera Antimicrobial Wound Dressings

Vomaris Innovations, Inc. announced today that it has entered into an exclusive global commercial partnership for its microcurrent generating wound care products, Procellera Antimicrobial Wound Dressings, for the Long Term Care market with Metrex, a professional consumables brand within Kavo Kerr Group, which is a member of the Danaher Corporation.

15 Sep 2015

NanoString announces key initiatives to expand market for nCounter Analysis System, related product portfolio

At a meeting with analysts and investors today, members of the senior management team of NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, plan to unveil the company’s strategic roadmap to drive continued growth and expand the market for its nCounter Analysis System and the related product portfolio.

From NanoString Technologies 14 Sep 2015

HealthSouth to offer $300M aggregate principal amount of senior notes through private placement

HealthSouth Corporation today announced it intends to offer through a private placement, subject to market and other conditions, $300 million aggregate principal amount of senior notes due 2025.

11 Sep 2015

ULURU signs definitive agreement to sell common stock to European investors

ULURU Inc., a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, today announced the signing of a definitive agreement to sell an aggregate of 4,079,539 shares of its common stock at a price per share of $0.38 to a group of European investors, which is expected to result in gross proceeds of $1,550,225.

11 Sep 2015

Business / Finance

TSX approves Aeterna Zentaris' Series B Warrant amendment

Genovate begins construction of Insulin Ecological Industrial Park in Changzhou National Hi-tech District

Apax-advised funds sign definitive agreement to acquire interest in Ideal Protein

Cryoport purchases IP rights to Cryoportal operating platform from Klatu

Florida Institute finalizes funding agreement with Aviana

ElastiMed raises $1 million investment

Johns Hopkins trained physicians create start-up to produce cheap generic drugs

Medgen completes acquisition of Alternaturals

PDL BioPharma purchases portion of royalties on expected sales of AcelRx's Zalviso

Palatin Technologies reports net loss of $12.1 million for fourth quarter 2015

Mölnlycke Health Care selects Mindtree to improve SAP application management

Takeda Pharmaceutical's $2.37 billion settlement over Actos drug moves forward

Glide Technologies, Cilian collaborate to develop solid dose formulation of recombinant influenza vaccine

Quethera receives seed investment funding to develop gene therapy for glaucoma

CardioDx announces national agreement with Quest Diagnostics to expand access to Corus CAD blood test

Immune Pharmaceuticals’ CEO establishes stock trading plan

Vomaris signs exclusive global commercial partnership with Metrex for Procellera Antimicrobial Wound Dressings

NanoString announces key initiatives to expand market for nCounter Analysis System, related product portfolio

HealthSouth to offer $300M aggregate principal amount of senior notes through private placement

ULURU signs definitive agreement to sell common stock to European investors

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News